From: Nephrotoxicity caused by colistin use in ICU: a single centre experience
Characteristics | Total (n = 148) | Non-AKI (n = 94) | AKI (n = 54) | p-value |
---|---|---|---|---|
Gender, n (%) | 1.000 | |||
Female | 38 (25.7) | 24 (25.5) | 14 (25.9) | |
Male | 110 (74.3) | 70 (74.5) | 40 (74.1) | |
Age, year, median (min-max) | 65 (21–91) | 61 (21–89) | 70.5 (40–91) | < 0.001 |
APACHE II score (when colistin therapy is started) (min-max) | 17 (2–49) | 16 (2–43) | 20.5 (5–49) | 0.004 |
ICU admission diagnosis n (%) | ||||
Pneumonia | 135 (91.2) | 86 (91.5) | 49 (90.7) | 1.000 |
Bloodstream infection | 11 (7.4) | 6 (6.4) | 5 (9.3) | 0.530 |
Urinary tract infection | 6 (4.1) | 5 (5.3) | 1 (1.9) | 0.416 |
Soft tissue infection | 4 (2.7) | 1 (1.1) | 3 (5.6) | 0.138 |
ICU admission CCI score, median (min-max) | 3 (0–10) | 3 (0–10) | 4 (0–9) | 0.002 |
Comorbidity, n (%) | 123 (83.1) | 75 (79.8) | 48 (88.9) | 0.232 |
HT | 37 (25) | 21 (22.3) | 16 (29.6) | 0.430 |
DM | 29 (19.6) | 19 (20.2) | 10 (18.5) | 0.972 |
CHF | 31 (20.9) | 15 (16) | 16 (29.6) | 0.079 |
COPD | 24 (16.2) | 18 (19.1) | 6 (11.1) | 0.296 |
CVD | 21 (14.2) | 11 (11.7) | 10 (18.5) | 0.368 |
Malignancy | 31 (20.9) | 19 (20.2) | 12 (22.2) | 0.937 |
CAD | 36 (24.3) | 20 (21.3) | 16 (29.6) | 0.347 |
ICU LOS, days, median (min-max) | 32 (3–178) | 32 (3–178) | 32 (4–128) | 0.484 |
Hospital LOS, days, median (min-max) | 41 (10–214) | 46 (11–214) | 39.5 (10–198) | 0.873 |
From onset of colistin to AKI development time, days, median (min-max) | 6 (1–29) | NA | 6 (1–29) | NA |
Duration of colistin treatment, days, median (min-max) | 12 (3–36) | 11.5 (3–30) | 13.5 (3–36) | 0.045 |
Duration of colistin treatment > 14 days, n (%) | 52 (35.1) | 29 (30.9) | 23 (42.6) | 0.207 |
Basal creatinine level, mg/dl, median (min-max) | 0.6 (0.2–1.2) | 0.6 (0.2–1.1) | 0.7 (0.2–1.2) | 0.027 |
KDIGO, n (%) | NA | |||
Stage-I | 10 (18.5) | NA | 10 (18.5) | |
Stage-II | 15 (27.8) | NA | 15 (27.8) | |
Stage-III | 29 (53.7) | NA | 29 (53.7) | |
Haemodialysis, n (%) | ||||
IHD | 7 (4.7) | NA | 6 (4) | |
CRRT | ||||
Vasopressor use, n (%) | 60 (40.5) | 28 (29.8) | 32 (59.3) | < 0.001 |
Mortality, n (%) | 58 (39.2) | 28 (29.8) | 30 (55.6) | 0.004 |